Precigen Inc (PGEN) Stock Price, Quote & News

Company Profile

Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell t...

Industry: Biotechnology

Sector: Healthcare

Phone: 301 556 9900

Website: precigen.com

Address:

20374 Seneca Meadows Parkway, Germantown, United States

Vic1931 May. 12 at 10:47 PM

$SLS Just tuning. 57 mil short...😅...based on dollar volume short reported, meh....roughly $800 mil 🤔 comes to anything between $4.25-$4.95 short entry. Just kneel down and pray $PGEN to do bad, which I doubt. Their ER is before the bell. They beat and could get contagious sector wise. If pre market volume gets hot I promise I will not laugh at anyone holding shorts on Sellas because you'll need more than shorts and shirts after you lose them. F*ck yeah I'm going to rotflmfao at you!

0 · Reply

M22 May. 12 at 8:00 PM

$PGEN ok maybe not. Let’s see what tomorrow brings 👍💎🤲🏻

0 · Reply

M22 May. 12 at 6:21 PM

$PGEN closes green today

0 · Reply

forgottenchuck May. 12 at 6:15 PM

$PGEN i cannot believe this stock is selling off a day before earnings. revenues are going to be the key and should make a monster move

3 · Reply

StockDad0927 May. 12 at 4:07 PM

$PGEN what a buying opportunity.

1 · Reply

dsup May. 12 at 2:32 AM

$PGEN https://www.linkedin.com/posts/precigen_asgct2026-raredisease-adenoverse-activity-7459588191101034498-PvG3?utm_medium=ios_app&rcm=ACoAAEIgdzEBKexZ4F9tMNrlLxi10PNW1csud-U&utm_source=social_share_send&utm_campaign=copy_link interesting. first conference i’ve seen them attend that isn’t focusing on Papz…. scheduled for day after earnings

1 · Reply

forgottenchuck May. 11 at 7:47 PM

$PGEN god i love this company, i use to hate it bigtime but the revenues coming in on there vaccine this wednesday should shock the markets

1 · Reply

M22 May. 11 at 5:00 PM

$PGEN ok I just completely sold out of $NU and took advantage of the lunchtime lull in Precigen and added another 5k shares. LFG 👍💎🤲

0 · Reply

CoffeeRocks May. 11 at 2:26 PM

$CODX $VRAX $BTAI $PGEN $THC 1.5$-2.6$ not bad not bad

1 · Reply

CoffeeRocks May. 11 at 2:17 PM

$BTAI $CODX $INHD $INO $PGEN Let’s get IT!!!!!

0 · Reply

Precigen to Announce First Quarter 2026 Financial Results and Provide Business Updates on May 13

2026-04-07T12:02:54.000Z - 5 weeks ago

Precigen sees Q1 revenue exceeding $18M, consensus $20.8M

2026-04-07T11:17:44.000Z - 5 weeks ago

Precigen sees ‘robust uptake’ in usage of Papzimeos since its launch

Apr 7, 2026, 7:00 AM EDT - 5 weeks ago

Precigen Reports 'Robust Uptake' of New Drug for Rare Respiratory Disease; First Quarter Revenue Expected to Top $18 Million

Mar 31, 2026, 11:00 AM EDT - 6 weeks ago

Precigen Transcript: Fireside chat

Mar 30, 2026, 8:30 AM EDT - 6 weeks ago

Precigen to Participate in a Fireside Chat with H.C. Wainwright on March 31

2026-03-26T15:25:13.000Z - 6 weeks ago

Precigen jumps on Q1 outlook despite earnings miss

2026-03-26T10:10:56.000Z - 6 weeks ago

Precigen price target raised to $10 from $9 at H.C. Wainwright

2026-03-26T10:00:46.000Z - 6 weeks ago

Precigen price target raised to $9 from $8 at Citizens

Mar 25, 2026, 4:30 PM EDT - 6 weeks ago

Precigen Earnings Call Transcript: Q4 2025

Mar 25, 2026, 4:05 PM EDT - 6 weeks ago

Precigen Reports Full Year 2025 Financial Results and Business Updates

2026-03-25T12:05:16.000Z - 7 weeks ago

Options Volatility and Implied Earnings Moves Today, March 25, 2026

BYND BZUN CHWY CTAS JEF KC PAYX

Mar 11, 2026, 4:05 PM EDT - 2 months ago

Precigen to Announce Full Year 2025 Financial Results and Provide Business Updates on March 25

Jan 20, 2026, 8:05 AM EST - 4 months ago

New Expert Consensus Published in The Laryngoscope Recommends PAPZIMEOS (zopapogene imadenovec) as the New Standard of Care First-Line Treatment for Adults with Recurrent Respiratory Papillomatosis

Jan 15, 2026, 10:30 AM EST - 4 months ago

Precigen Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 8:00 AM EST - 4 months ago

Precigen Showcases Rapid Commercialization Momentum and Growing Market Adoption of First-and-Only FDA-Approved Therapy for RRP at the 44th Annual J.P. Morgan Healthcare Conference

Jan 5, 2026, 4:05 PM EST - 4 months ago

Precigen to Present at the 44th Annual J.P. Morgan Healthcare Conference

2025-12-03T15:00:13.000Z - 5 months ago

JPMorgan healthcare analysts hold an analyst/industry conference call

2025-11-14T11:16:04.000Z - 6 months ago

Precigen price target raised to $9 from $8.50 at H.C. Wainwright

2025-11-13T21:31:56.000Z - 6 months ago

Precigen reports Q3 EPS ($1.06) vs. (9c) last year

Nov 13, 2025, 4:30 PM EST - 6 months ago

Precigen Earnings Call Transcript: Q3 2025

Nov 13, 2025, 4:05 PM EST - 6 months ago

Precigen Reports Third Quarter 2025 Financial Results and Business Updates

Nov 6, 2025, 4:30 PM EST - 6 months ago

Precigen to Announce Third Quarter 2025 Financial Results and Provide Business Updates on November 13

2025-10-13T11:05:34.000Z - 7 months ago

Precigen presents long-term data demonstrating durable responses to PAPZIMEOS

Oct 13, 2025, 7:00 AM EDT - 7 months ago

Precigen Announces Long-Term Follow-Up Results Highlighting Ongoing Durable Complete Responses after Treatment with PAPZIMEOS, the First and Only FDA-approved Therapy for Adults with Recurrent Respiratory Papillomatosis

Sep 3, 2025, 7:00 AM EDT - 9 months ago

Precigen Announces Up to $125 Million Non-Dilutive Financing

Sep 2, 2025, 11:00 AM EDT - 9 months ago

Precigen Transcript: Fireside Chat

Aug 25, 2025, 8:05 AM EDT - 9 months ago

Precigen to Participate in Upcoming Virtual Fireside Chats Hosted by Cantor and H.C. Wainwright

2025-08-19T21:35:16.000Z - 9 months ago

Precigen files to sell 143.81M shares of common stock for holders

2025-08-19T09:40:13.000Z - 9 months ago

Precigen price target raised to $8 from $6 at Citizens JMP

2025-08-18T13:40:19.000Z - 9 months ago

Unusually active option classes on open August 18th

AG BBAI FSLR IQ NVAX NVO PCG

Aug 18, 2025, 8:00 AM EDT - 9 months ago

Precigen Transcript: Investor Update

2025-08-15T23:57:00.000Z - 9 months ago

Precigen Stock (PGEN) Roars Over 60% Higher on FDA Green Light for Papzimeos Therapy

2025-08-15T13:01:20.000Z - 9 months ago

Morning Movers: Precigen surges following full FDA approval of Papzimeos

AMAT DHI FLO FUFU INTC LEN SNDK

Aug 15, 2025, 7:18 AM EDT - 9 months ago

US FDA approves Precigen's immunotherapy for rare respiratory disease

Aug 15, 2025, 7:00 AM EDT - 9 months ago

Precigen Announces Full FDA Approval of PAPZIMEOS (zopapogene imadenovec-drba), the First and Only Approved Therapy for the Treatment of Adults with Recurrent Respiratory Papillomatosis

May 14, 2025, 4:05 PM EDT - 1 year ago

Precigen Reports First Quarter 2025 Financial Results and Business Updates

Apr 16, 2025, 8:05 AM EDT - 1 year ago

Precigen and Recurrent Respiratory Papillomatosis Foundation to Host the 2025 International RRP Awareness Day on June 11th

Mar 19, 2025, 4:30 PM EDT - 1 year ago

Precigen Earnings Call Transcript: Q4 2024

Mar 19, 2025, 4:05 PM EDT - 1 year ago

Precigen Reports Full Year 2024 Financial Results and Business Updates

Mar 13, 2025, 8:05 AM EDT - 1 year ago

Precigen to Announce Full Year 2024 Financial Results and Provide Business Updates on March 19th

Feb 25, 2025, 8:05 AM EST - 1 year ago

FDA Grants Priority Review to Precigen's BLA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis with PDUFA Target Action Date Set for August 27, 2025

Jan 16, 2025, 12:00 PM EST - 1 year ago

Precigen Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 13, 2025, 7:00 AM EST - 1 year ago

Precigen to Present Plans for Realizing Commercial Vision for PRGN-2012 at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 9, 2025, 8:30 AM EST - 1 year ago

Precigen to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 30, 2024, 7:00 AM EST - 1 year ago

Precigen Completes Submission of BLA with Request for Priority Review to the FDA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis

Dec 27, 2024, 9:00 AM EST - 1 year ago

Precigen Announces $79.0 Million Private Placement Offering of Convertible Preferred Stock

Nov 19, 2024, 10:55 AM EST - 1 year ago

Precigen Transcript: Stifel 2024 Healthcare Conference

Nov 14, 2024, 4:30 PM EST - 1 year ago

Precigen Reports Third Quarter 2024 Financial Results and Business Updates

Nov 12, 2024, 4:05 PM EST - 1 year ago

Precigen to Participate in the Stifel 2024 Healthcare Conference

Sep 16, 2024, 4:30 PM EDT - 1 year ago

Precigen to Participate in the 2024 Cantor Global Healthcare Conference

Aug 14, 2024, 4:30 PM EDT - 1 year ago

Precigen Earnings Call Transcript: Q2 2024

Aug 14, 2024, 4:05 PM EDT - 1 year ago

Precigen Reports Second Quarter and First Half 2024 Financial Results and Business Updates

Aug 9, 2024, 8:00 AM EDT - 1 year ago

Precigen to Announce Second Quarter and First Half 2024 Financial Results on August 14th

Aug 7, 2024, 9:30 PM EDT - 1 year ago

Precigen Announces Pricing of $30.0 Million Public Offering of Common Stock

Aug 6, 2024, 4:04 PM EDT - 1 year ago

Precigen Announces Proposed $30 Million Public Offering of Common Stock

Aug 6, 2024, 4:01 PM EDT - 1 year ago

Precigen Strategically Prioritizes Portfolio to Focus on First Potential Gene Therapy Launch

Jul 23, 2024, 8:01 AM EDT - 1 year ago

Precigen Appoints Phil Tennant as Chief Commercial Officer to Spearhead First Potential Gene Therapy Launch

Jun 3, 2024, 7:00 PM EDT - 2 years ago

Precigen Transcript: Study Result

Jun 3, 2024, 9:30 AM EDT - 2 years ago

Precigen Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More than Half of Patients Achieved Complete Response

May 23, 2024, 5:00 PM EDT - 2 years ago

Precigen to Host a Webcast on June 3rd to Detail Pivotal Study Results of PRGN-2012 in Recurrent Respiratory Papillomatosis Presented at the 2024 ASCO Annual Meeting

May 14, 2024, 4:05 PM EDT - 2 years ago

Precigen Reports First Quarter 2024 Financial Results and Business Updates

May 8, 2024, 4:05 PM EDT - 2 years ago

Precigen to Announce First Quarter 2024 Financial Results on May 14th and Host a Conference Call on June 3rd following the Late-breaking Oral Presentation for PRGN-2012 at the 2024 ASCO Annual Meeting

Apr 24, 2024, 10:20 AM EDT - 2 years ago

Precigen to Present Late-breaking Abstract for Pivotal Phase 2 Study Data for PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Patients with Recurrent Respiratory Papillomatosis at the 2024 ASCO Annual Meeting

Apr 24, 2024, 9:00 AM EDT - 2 years ago

Actym Therapeutics Appoints Thomas Smart as CEO

ANAB XOMA

Mar 28, 2024, 4:05 PM EDT - 2 years ago

Precigen and Recurrent Respiratory Papillomatosis Foundation to Hold Inaugural International RRP Awareness Day on June 11th

Mar 19, 2024, 4:30 PM EDT - 2 years ago

Precigen Earnings Call Transcript: Q4 2023

Mar 19, 2024, 4:05 PM EDT - 2 years ago

Precigen Reports Full Year 2023 Financial Results and Business Updates

Mar 12, 2024, 4:05 PM EDT - 2 years ago

Precigen to Participate in a Fireside Chat Hosted by Cantor Fitzgerald to Discuss PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis

Mar 5, 2024, 4:05 PM EST - 2 years ago

Precigen to Announce Fourth Quarter and Full Year 2023 Financial Results on March 19th

Feb 13, 2024, 3:20 PM EST - 2 years ago

Precigen Transcript: Oppenheimer 34th Annual Healthcare Life Sciences Conference (Virtual)

Feb 6, 2024, 4:05 PM EST - 2 years ago

Precigen to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Jan 16, 2024, 8:05 AM EST - 2 years ago

Precigen Receives Orphan Drug Designation for PRGN-2012 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission

Jan 10, 2024, 8:15 PM EST - 2 years ago

Precigen Transcript: J.P. Morgan 42nd Annual Healthcare Conference 2024

Jan 8, 2024, 8:30 AM EST - 2 years ago

Precigen Highlights Pipeline Updates to be Presented at the 42nd Annual J.P. Morgan Healthcare Conference

Dec 18, 2023, 4:05 PM EST - 2 years ago

Precigen to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Dec 6, 2023, 3:00 PM EST - 2 years ago

Precigen Transcript: The JMP Securities Hematology and Oncology Summit

Nov 29, 2023, 4:05 PM EST - 2 years ago

Precigen to Participate in the JMP Securities Hematology and Oncology Summit

Nov 15, 2023, 10:55 AM EST - 2 years ago

Precigen Transcript: Stifel 2023 Annual Healthcare Conference

Nov 9, 2023, 4:55 PM EST - 2 years ago

Precigen Reports Third Quarter 2023 Financial Results and Progress of Clinical Programs

Nov 7, 2023, 4:05 PM EST - 2 years ago

Precigen to Participate in the Stifel 2023 Healthcare Conference

Vic1931 May. 12 at 10:47 PM

0 · Reply

M22 May. 12 at 8:00 PM

$PGEN ok maybe not. Let’s see what tomorrow brings 👍💎🤲🏻

0 · Reply

M22 May. 12 at 6:21 PM

$PGEN closes green today

0 · Reply

forgottenchuck May. 12 at 6:15 PM

$PGEN i cannot believe this stock is selling off a day before earnings. revenues are going to be the key and should make a monster move

3 · Reply

StockDad0927 May. 12 at 4:07 PM

$PGEN what a buying opportunity.

1 · Reply

dsup May. 12 at 2:32 AM

1 · Reply

forgottenchuck May. 11 at 7:47 PM

$PGEN god i love this company, i use to hate it bigtime but the revenues coming in on there vaccine this wednesday should shock the markets

1 · Reply

M22 May. 11 at 5:00 PM

$PGEN ok I just completely sold out of $NU and took advantage of the lunchtime lull in Precigen and added another 5k shares. LFG 👍💎🤲

0 · Reply

CoffeeRocks May. 11 at 2:26 PM

$CODX $VRAX $BTAI $PGEN $THC 1.5$-2.6$ not bad not bad

1 · Reply

CoffeeRocks May. 11 at 2:17 PM

$BTAI $CODX $INHD $INO $PGEN Let’s get IT!!!!!

0 · Reply

CoffeeRocks May. 11 at 11:39 AM

$BTAI $CODX $INHD $INO $PGEN Picks CODX fda approval at home tests BTAI earnings waiting for approval at 🏡 test INO earnings PGEN earnings

1 · Reply

RayD73 May. 11 at 10:51 AM

$PGEN While the Q1 results are important, the guidance is much more important given that the J-Code took effect on April 1st. They should be able to discuss the acceleration in "onboarding" and project revenue for Q2 and beyond. Looking for new highs this week.

1 · Reply

chungana May. 10 at 8:28 PM

$PGEN With Inovio earning’s call same day as Precigen’s, I’m sure Helen is going to want to bring some really big news/numbers this week to blunt whatever Inovio may report, and keep the her foot on their neck in the RRP space.

0 · Reply

Jason_Craps May. 10 at 7:49 PM

$PGEN Helen has guided to over $18 million in Q1. The Street’s consensus is at $20 million. 500 registered in the hub and $24 million would make me happy.

1 · Reply

chungana May. 10 at 4:21 PM

$PGEN For the CEO to confidently guide over $19 million, she must know they had at least 45 patients ready for dosing in 1st Q…To beat street estimates, they need another 5 patients dosed. Hopefully, this CEO is an honest one, unlike so many others in this business…Could be a significant beat if they ramped up treatments after 4th Q…2nd Q., with J-code in place, company should blow past $30 million…👍

2 · Reply

BTG007 May. 9 at 9:13 PM

$PGEN buying on dips- this will pay off longer term- SOC- or you can go under the knife multiple times a year and let a surgeon cut these growths out of your throat- um, no thanks

0 · Reply

RayD73 May. 8 at 8:11 PM

$PGEN Massive volume at the close. Getting positioned for a blowout quarter and guidance.

0 · Reply

wallstbullinfinity May. 8 at 7:57 PM

$INO 20 Million VOLUME 😮 these past days been crazy 🧬🧬🧬🌏🌍🌎 $PGEN $MRNA $NVAX

1 · Reply

wallstbullinfinity May. 8 at 6:10 PM

$INO 16 MILLION VOLUME... HOLY FUHK 🤯 🧬🧬🧬🌏🌍🌎 $PGEN $NVAX $MRNA

0 · Reply

Martee_Pharma_Stocks May. 8 at 5:25 PM

$PGEN taking off

1 · Reply

wallstbullinfinity May. 8 at 4:57 PM

$INO Inovio volume just NASTY THIS WEEK 🧬🧬🧬🌏🌍🌎 $PGEN $MRNA $NVAX

0 · Reply

RayD73 May. 8 at 4:44 PM

$PGEN Last few days to get in on what I believe will be a most attractive price on PGEN. Next week's earnings and cc should clear the way for a bullish move to new highs.

1 · Reply

Market Cap	1.50B
Revenue (ttm)	9.68M
Net Income (ttm)	-250.64M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	210.50
Profit Margin	-2,589.26%
Debt to Equity Ratio	4.46

Volume	2,322,100
Avg Vol	4,155,204
Day's Range	N/A - N/A
Shares Out	356.51M
Stochastic %K	16%
Beta	1.07
Analysts	Sell
Price Target	$9.50